ShareValue scores for 688765.SHG: Valuation 44, Quality 38, Growth 50, Health 34.
688765.SHGSSE
Wuhan Healthgen Biotechnology Corp.
CN¥31.11
(-3.39%)
Updated
688765.SHGSSE
Wuhan Healthgen Biotechnology Corp.
Updated
Pulse
Pulse
Fundamental Rating
Value Trap Risk
If P/E met sector median
Rating
Trap Risk
P/E to median
vs Shanghai-listed Healthcare stocks
Company Details
Wuhan Healthgen Biotechnology Corp. engages in the research and development of molecular pharmaceuticals in China. The company offers recombinant human serum albumin, proteins for cosmetics ingredients, and other recombinant proteins. It also provides recombinant growth factors, such as recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human insulin-like growth factor-1 LR3, recombinant human vascular endothelial, recombinant human keratinocyte growth factor, recombinant human fibronectin, recombinant human a-1 antitrypsin, recombinant human lactoferrin, recombinant human epidermal growth factor, and recombinant human fibronectin. In addition, it provides recombinant protein expression, purification process development, and detection methodology services. The company was founded in 2006 and is based in Wuhan, China.
Score Analysis
AI Investment Thesis
Valuation looks fairly valued against Shanghai-listed Healthcare stocks, though its P/B of 3.87 is higher than 72% of peers, with P/E and EV/EBITDA not available.
Quality is the weak pillar: revenue of just CN¥27.8 million against a CN¥10.9 billion market cap leaves P/S at 465.78 versus a 5.3 global sector average, and losses persist.
Third-quarter results published 27 October 2026 showed revenue up 41.55% to CN¥27.83 million but a CN¥106 million net loss, with R&D spending up 15.50%.